Director/PDMR Shareholding

Smith & Nephew Plc
11 November 2024
 

SMITH & NEPHEW PLC

 

11 November 2024

 

NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.

 

Reason for the notification

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Smith & Nephew plc

LEI

213800ZTMDN8S67S1H61

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Smith & Nephew plc ordinary shares of USD 0.20 each

Identification code

ISIN: GB0009223206

Nature of the transaction

Purchase of ordinary shares through the Company's Dividend Re-Investment Plan following the 2024 interim dividend payment on 8 November 2024.

Date of Transaction

2024 - 11 - 08

Place of Transaction

London Stock Exchange (XLON)

 

Name

(Position)

Director / PDMR

Price

Volume

Aggregated information

Helen Barraclough

(Group General Counsel and Company Secretary)

PDMR

9.234

 

421.23522

N/A Single Transaction

Paul Connolly

(President, Global Operations)

PDMR

9.234

 

194.91162

 

N/A Single Transaction

Phil Cowdy

Chief Corporate Development & Corporate Affairs Officer

PDMR

9.234

 

1.9035

N/A Single Transaction

Mizanu Kebede

(Chief Quality & Regulatory Affairs Officer)

PDMR

9.234

 

111.64316

 

N/A Single Transaction

Deepak Nath

(Chief Executive Officer)

Director

9.234

 

1924.20518

 

N/A Single Transaction

Scott Schaffner

(President, Sports Medicine)

PDMR

9.234

 

794.95718

N/A Single Transaction

 

 

 

 

Helen Barraclough

General Counsel and Company Secretary

Smith & Nephew plc

 

Tel:  +44 (0)1923 477100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings